Contributo scientifico, sviluppato generalmente su uno specifico argomento, che illustra risultati originali di una ricerca o presenta caratteristiche di review, cioè di discussione dello stato dell’arte o della letteratura entro un ambito scientifico definito. La rivista di pubblicazione deve presentare caratteristiche di scientificità. La tipologia non comprende editoriali, commenti brevi, repliche, abstract, errata, recensioni e prodotti similari, per i quali sono previste specifiche tipologie.
Regulatory evaluation of Glybera in Europe-two committees, one mission
2013 Melchiorri, D; Pani, L; Gasparini, P; Cossu, G; Ancans, J; Borg, Jj; Drai, C; Fiedor, P; Flory, E; Hudson, I; Leufkens, Hg; Müller-Berghaus, J; Narayanan, G; Neugebauer, B; Pokrotnieks, J; Robert, Jl; Salmonson, T; Schneider, Ck.
Insights Into the Decision Making of Advisory Groups to the Italian Medicines Agency
2014 Marangi, M.; Cammarata, S. M.; Pani, L.
Rare diseases and effective treatments: Are we delivering?
2015 Luzzatto, L.; Hollak, C. E. M.; Cox, T. M.; Schieppati, A.; Licht, C.; Kaariainen, H.; Merlini, G.; Schaefer, F.; Simoens, S.; Pani, L.; Garattini, S.; Remuzzi, G.
The European Medicines Agency's strategies to meet the challenges of Alzheimer disease
2015 Haas, M.; Mantua, V.; Haberkamp, M.; Pani, L.; Isaac, M.; Butlen-Ducuing, F.; Vamvakas, S.; Broich, K.
Daptomycin in paediatrics: Current knowledge and the need for future research
2015 Principi, N.; Caironi, M.; Venturini, F.; Pani, L.; Esposito, S.
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease
2015 Bradley, P.; Akehurst, R.; Ballard, C.; Banerjee, S.; Blennow, K.; Bremner, J.; Broich, K.; Cummings, J.; Dening, K.; Dubois, B.; Klipper, W.; Leibman, C.; Mantua, V.; Molinuevo, J. L.; Morgan, S.; Muscolo, L. A. A.; Nicolas, F.; Pani, L.; Robinson, L.; Siviero, P.; Van Dam, J.; Van Emelen, J.; Wimo, A.; Wortmann, M.; Goh, L.
Generic and biosilimilar medicines use and expenditure: A report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA)
2015 Monaco, A.; Mammarella, F.; Cangini, A.; Marini, R.; Marengoni, A.; Russo, P.; Pecorelli, S.; Pani, L.
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin
2015 Gianoncelli, A.; Bonini, S. A.; Bertuzzi, M.; Guarienti, M.; Vezzoli, S.; Kumar, R.; Delbarba, A.; Mastinu, A.; Sigala, S.; Spano, P.; Pani, L.; Pecorelli, S.; Memo, M.
Validated method to determine quetiapine and norquetiapine in microsomal matrix by LC MS-MS: Implication in quetiapine metabolism
2014 Peddio, G.; Pittau, B; Manca, I.; Salis, R.; Pani, L.; Pira, L.
Effectiveness and cost effectiveness of bevacizumab in metastatic colorectal cancer
2015 Messori, A.; De Rosa, M.; Fadda, V.; Pani, L.
Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model
2015 Guarienti, M.; Giacopuzzi, E.; Gianoncelli, A.; Sigala, S.; Spano, P.; Pecorelli, S.; Pani, L.; Memo, M.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance
2015 Renda, F.; Landoni, G.; Bertini Malgarini, R.; Assisi, A.; Azzolini, M. L.; Mucchetti, M.; Pimpinella, G.; Pani, L.
Monitoring registries at Italian medicines agency: Fostering access, guaranteeing sustainability
2015 Montilla, S.; Xoxi, E.; Russo, P.; Cicchetti, A.; Pani, L.
Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database
2016 Renda, F.; Landoni, G.; Trotta, F.; Piras, D.; Finco, G.; Felicetti, P.; Pimpinella, G.; Pani, L.
Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency
2016 Onder, G.; Marengoni, A.; Russo, P.; Degli Esposti, L.; Fini, M.; Monaco, A.; Bonassi, S.; Palmer, K.; Marrocco, W.; Pozzi, G.; Sangiorgi, D.; Buda, S.; Marchionni, N.; Mammarella, F.; Bernabei, R.; Pani, L.; Pecorelli, S.
Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR)
2016 Pani, L.; Montilla, S.; Nemeth, G.; Russo, P.; Viceconte, G.; Vogler, S.
Kounis syndrome due to antibiotics: A global overview from pharmacovigilance databases
2016 Renda, F.; Marotta, E.; Landoni, G.; Belletti, A.; Cuconato, V.; Pani, L.
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
2019 Kuypers, K. P. C.; Ng, L.; Erritzoe, D.; Knudsen, G. M.; Nichols, C. D.; Nichols, D. E.; Pani, L.; Soula, A.; Nutt, D.
Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues
2019 Pani, L.; Keefe, R. S. E.
Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
2020 Trifiro, G.; Crisafulli, S.; Ando, G.; Racagni, G.; Drago, F.; Berrino, L.; Re, M.; Bernardini, R.; Chiamulera, C.; D'Avolio, A.; Pani, L.; Clementi, E.; Capuano, A.; Scaglione, F.; Danesi, R.; Cirino, G.; Mugelli, A.; Bonanno, G.; Brunello, N.; Luca, A.; Hrelia, P.; Pistis, M.; Ghelardini, C.; Taglialatela, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Regulatory evaluation of Glybera in Europe-two committees, one mission | 1-gen-2013 | Melchiorri, D; Pani, L; Gasparini, P; Cossu, G; Ancans, J; Borg, Jj; Drai, C; Fiedor, P; Flory, E; Hudson, I; Leufkens, Hg; Müller-Berghaus, J; Narayanan, G; Neugebauer, B; Pokrotnieks, J; Robert, Jl; Salmonson, T; Schneider, Ck. | |
| Insights Into the Decision Making of Advisory Groups to the Italian Medicines Agency | 1-gen-2014 | Marangi, M.; Cammarata, S. M.; Pani, L. | |
| Rare diseases and effective treatments: Are we delivering? | 1-gen-2015 | Luzzatto, L.; Hollak, C. E. M.; Cox, T. M.; Schieppati, A.; Licht, C.; Kaariainen, H.; Merlini, G.; Schaefer, F.; Simoens, S.; Pani, L.; Garattini, S.; Remuzzi, G. | |
| The European Medicines Agency's strategies to meet the challenges of Alzheimer disease | 1-gen-2015 | Haas, M.; Mantua, V.; Haberkamp, M.; Pani, L.; Isaac, M.; Butlen-Ducuing, F.; Vamvakas, S.; Broich, K. | |
| Daptomycin in paediatrics: Current knowledge and the need for future research | 1-gen-2015 | Principi, N.; Caironi, M.; Venturini, F.; Pani, L.; Esposito, S. | |
| Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease | 1-gen-2015 | Bradley, P.; Akehurst, R.; Ballard, C.; Banerjee, S.; Blennow, K.; Bremner, J.; Broich, K.; Cummings, J.; Dening, K.; Dubois, B.; Klipper, W.; Leibman, C.; Mantua, V.; Molinuevo, J. L.; Morgan, S.; Muscolo, L. A. A.; Nicolas, F.; Pani, L.; Robinson, L.; Siviero, P.; Van Dam, J.; Van Emelen, J.; Wimo, A.; Wortmann, M.; Goh, L. | |
| Generic and biosilimilar medicines use and expenditure: A report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA) | 1-gen-2015 | Monaco, A.; Mammarella, F.; Cangini, A.; Marini, R.; Marengoni, A.; Russo, P.; Pecorelli, S.; Pani, L. | |
| An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin | 1-gen-2015 | Gianoncelli, A.; Bonini, S. A.; Bertuzzi, M.; Guarienti, M.; Vezzoli, S.; Kumar, R.; Delbarba, A.; Mastinu, A.; Sigala, S.; Spano, P.; Pani, L.; Pecorelli, S.; Memo, M. | |
| Validated method to determine quetiapine and norquetiapine in microsomal matrix by LC MS-MS: Implication in quetiapine metabolism | 1-gen-2014 | Peddio, G.; Pittau, B; Manca, I.; Salis, R.; Pani, L.; Pira, L. | |
| Effectiveness and cost effectiveness of bevacizumab in metastatic colorectal cancer | 1-gen-2015 | Messori, A.; De Rosa, M.; Fadda, V.; Pani, L. | |
| Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model | 1-gen-2015 | Guarienti, M.; Giacopuzzi, E.; Gianoncelli, A.; Sigala, S.; Spano, P.; Pecorelli, S.; Pani, L.; Memo, M. | |
| Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance | 1-gen-2015 | Renda, F.; Landoni, G.; Bertini Malgarini, R.; Assisi, A.; Azzolini, M. L.; Mucchetti, M.; Pimpinella, G.; Pani, L. | |
| Monitoring registries at Italian medicines agency: Fostering access, guaranteeing sustainability | 1-gen-2015 | Montilla, S.; Xoxi, E.; Russo, P.; Cicchetti, A.; Pani, L. | |
| Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database | 1-gen-2016 | Renda, F.; Landoni, G.; Trotta, F.; Piras, D.; Finco, G.; Felicetti, P.; Pimpinella, G.; Pani, L. | |
| Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency | 1-gen-2016 | Onder, G.; Marengoni, A.; Russo, P.; Degli Esposti, L.; Fini, M.; Monaco, A.; Bonassi, S.; Palmer, K.; Marrocco, W.; Pozzi, G.; Sangiorgi, D.; Buda, S.; Marchionni, N.; Mammarella, F.; Bernabei, R.; Pani, L.; Pecorelli, S. | |
| Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR) | 1-gen-2016 | Pani, L.; Montilla, S.; Nemeth, G.; Russo, P.; Viceconte, G.; Vogler, S. | |
| Kounis syndrome due to antibiotics: A global overview from pharmacovigilance databases | 1-gen-2016 | Renda, F.; Marotta, E.; Landoni, G.; Belletti, A.; Cuconato, V.; Pani, L. | |
| Microdosing psychedelics: More questions than answers? An overview and suggestions for future research | 1-gen-2019 | Kuypers, K. P. C.; Ng, L.; Erritzoe, D.; Knudsen, G. M.; Nichols, C. D.; Nichols, D. E.; Pani, L.; Soula, A.; Nutt, D. | |
| Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues | 1-gen-2019 | Pani, L.; Keefe, R. S. E. | |
| Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? | 1-gen-2020 | Trifiro, G.; Crisafulli, S.; Ando, G.; Racagni, G.; Drago, F.; Berrino, L.; Re, M.; Bernardini, R.; Chiamulera, C.; D'Avolio, A.; Pani, L.; Clementi, E.; Capuano, A.; Scaglione, F.; Danesi, R.; Cirino, G.; Mugelli, A.; Bonanno, G.; Brunello, N.; Luca, A.; Hrelia, P.; Pistis, M.; Ghelardini, C.; Taglialatela, M. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- Contributo su RIVISTA69890
- Atti di CONVEGNO1
- Contributo su VOLUME1
Data di pubblicazione
- 2020 - 202720225
- 2010 - 201923518
- 2000 - 200914314
- 1990 - 19998032
- 1980 - 19893149
- 1970 - 1979640
- 1966 - 196911
Editore
- Elsevier BV:PO Box 211, 1000 AE A...334
- American Institute of Physics:2 H...226
- Elsevier Science Limited:Oxford F...189
- Giuffre Editore Spa:via Busto Ars...101
- Societa Editrice il Mulino Spa:St...73
- Springer Verlag Germany:Tiergarte...71
- IEEE / Institute of Electrical an...70
- Academic Press Incorporated:6277 ...67
- American Chemical Society:1155 Si...63
- Edizioni Minerva Medica:Corso Bra...59
Rivista
- JOURNAL OF HIGH ENERGY PHYSICS404
- EFSA JOURNAL380
- PLOS ONE315
- PHYSICAL REVIEW LETTERS309
- PHYSICAL REVIEW. B, CONDENSED MAT...294
- SCIENTIFIC REPORTS290
Serie
- EUROPEAN DISTANCE AND E-LEARNING ...1
Keyword
- Humans4564
- Female2681
- Male2251
- Middle Aged1673
- Adult1526
- Aged1328
- Italy768
- Treatment Outcome649
- COVID-19587
- 80 and over506
Lingua
- eng58345
- ita10791
- fre334
- spa300
- ger189
- por61
- rus24
- und23
- chi15
- pol7
Accesso al fulltext
- no fulltext29938
- open19792
- reserved18705
- partially open1441
- embargoed15
- mixed1
